目的探讨microRNA-144细胞周期蛋白B1(miR-144CCNB1)信号调节通路在肝癌增殖、迁移和侵袭作用及其相关机制。方法以2011年1月~2016年1月我院收治的100例肝癌患者的肝癌组织和癌旁组织为研究标本,采用荧光定量PCR(qRT-PCR)法检测肝癌及...目的探讨microRNA-144细胞周期蛋白B1(miR-144CCNB1)信号调节通路在肝癌增殖、迁移和侵袭作用及其相关机制。方法以2011年1月~2016年1月我院收治的100例肝癌患者的肝癌组织和癌旁组织为研究标本,采用荧光定量PCR(qRT-PCR)法检测肝癌及其癌旁组织的miR-144表达和CCNB1蛋白表达情况,采用RNA干扰技术沉默CCNB1基因,并将靶向CCNB1的siRNA转染至肝癌细胞系HepG2和QGY-7703中,检测其对肝癌细胞生长、迁移和侵袭的生物学行为的影响。结果肝癌组织中miR-144表达较癌旁组织明显下调,CCNB1蛋白在肝癌组织的表达水平较癌旁组织明显上调,miR-144高表达者预后无瘤生存期较其低表达者明显长,而CCNB1蛋白低表达者无瘤生存期明显长于其高表达者,差异有统计学意义(P<0.05);与未处理者和阴性对照模拟物相较,转染CCNB1 siR肝癌细胞CCNB1蛋白表达水平明显下降;与未处理和阴性对照模拟物相较,转染CCBN1 siR HepG2细胞凋亡百分明显升高,转染CCNB1 siR HepG2细胞增殖能力明显下降,转染CCNB1siR HepG2细胞迁移能力明显降低;与阴性对照模拟物和未处理细胞相较,转染CCNB1-siR QGY-7703细胞克隆团数(成瘤能力)明显减少。结论 miR-144CCNB1信号调节通路在肝癌增殖、迁移和侵袭中发挥重要作用,其可能机制为miR-144负向调控CCNB1表达,从而影响肝癌细胞增殖、凋亡、迁移等生物学行为,为肝癌治疗的新靶点提供理论依据。展开更多
Background:Fuzheng Huayu capsule(FZHY)combined with antiviral treatment has been shown to significantly reduce the risk of liver cancer in patients with hepatitis B cirrhosis.However,the potential of FZHY to directly ...Background:Fuzheng Huayu capsule(FZHY)combined with antiviral treatment has been shown to significantly reduce the risk of liver cancer in patients with hepatitis B cirrhosis.However,the potential of FZHY to directly treat liver cancer remains largely unknown.This study aims to investigate the molecular mechanism underlying the potential of FZHY in treating liver cancer.Methods:A network pharmacological analysis was performed using the Traditional Chinese Medicine Systems Pharmacology database to identify FZHY compounds and targets.Disease targets were searched using the Genecards database,and transcriptome data was downloaded from the NCBI database.Gene Ontology analysis was conducted using the DAVID database,and Kyoto Encyclopedia of Genes and Genomes analysis was based on KOBAS and bioinformatics methods.The Swissdock database was used for molecular docking.In cell experiments,the half inhibitory concentration(IC50)of FZHY was determined using the CCK8 method.The effects of FZHY on cell viability,apoptosis,and mitochondrial membrane potential were evaluated using a fluorescence microscope and flow cytometry.The molecular mechanism of FZHY in treating liver cancer was verified using quantitative polymerase chain reaction.Results:A total of 127 compounds and 184 proteins were identified as potential active ingredients and putative liver cancer-related targets.Additionally,1,899 liver cancer targets,279 transcriptome targets,and 3 pathways(p53 signaling pathway,apoptosis and PI3K-Akt pathway)were collected.The FZHY-targets-liver cancer interaction network was constructed.IC50 of FZHY lyophilized powder solution to liver cancer was 5.13 mg/mL(IC50=5.13 mg/mL).FZHY treatment led to an increase in the ratio of cell apoptosis and induced mitochondrial membrane potential damage,resulting in an increase in the number of dead cells.The expression levels of CCNB1 and BIRC5 were induced with FZHY treatment,while the expression levels of AKR1C3 and IGF2 were reduced.Conclusion:FZHY promotes apoptosis of liver cancer cells 展开更多
文摘目的探讨microRNA-144细胞周期蛋白B1(miR-144CCNB1)信号调节通路在肝癌增殖、迁移和侵袭作用及其相关机制。方法以2011年1月~2016年1月我院收治的100例肝癌患者的肝癌组织和癌旁组织为研究标本,采用荧光定量PCR(qRT-PCR)法检测肝癌及其癌旁组织的miR-144表达和CCNB1蛋白表达情况,采用RNA干扰技术沉默CCNB1基因,并将靶向CCNB1的siRNA转染至肝癌细胞系HepG2和QGY-7703中,检测其对肝癌细胞生长、迁移和侵袭的生物学行为的影响。结果肝癌组织中miR-144表达较癌旁组织明显下调,CCNB1蛋白在肝癌组织的表达水平较癌旁组织明显上调,miR-144高表达者预后无瘤生存期较其低表达者明显长,而CCNB1蛋白低表达者无瘤生存期明显长于其高表达者,差异有统计学意义(P<0.05);与未处理者和阴性对照模拟物相较,转染CCNB1 siR肝癌细胞CCNB1蛋白表达水平明显下降;与未处理和阴性对照模拟物相较,转染CCBN1 siR HepG2细胞凋亡百分明显升高,转染CCNB1 siR HepG2细胞增殖能力明显下降,转染CCNB1siR HepG2细胞迁移能力明显降低;与阴性对照模拟物和未处理细胞相较,转染CCNB1-siR QGY-7703细胞克隆团数(成瘤能力)明显减少。结论 miR-144CCNB1信号调节通路在肝癌增殖、迁移和侵袭中发挥重要作用,其可能机制为miR-144负向调控CCNB1表达,从而影响肝癌细胞增殖、凋亡、迁移等生物学行为,为肝癌治疗的新靶点提供理论依据。
文摘Background:Fuzheng Huayu capsule(FZHY)combined with antiviral treatment has been shown to significantly reduce the risk of liver cancer in patients with hepatitis B cirrhosis.However,the potential of FZHY to directly treat liver cancer remains largely unknown.This study aims to investigate the molecular mechanism underlying the potential of FZHY in treating liver cancer.Methods:A network pharmacological analysis was performed using the Traditional Chinese Medicine Systems Pharmacology database to identify FZHY compounds and targets.Disease targets were searched using the Genecards database,and transcriptome data was downloaded from the NCBI database.Gene Ontology analysis was conducted using the DAVID database,and Kyoto Encyclopedia of Genes and Genomes analysis was based on KOBAS and bioinformatics methods.The Swissdock database was used for molecular docking.In cell experiments,the half inhibitory concentration(IC50)of FZHY was determined using the CCK8 method.The effects of FZHY on cell viability,apoptosis,and mitochondrial membrane potential were evaluated using a fluorescence microscope and flow cytometry.The molecular mechanism of FZHY in treating liver cancer was verified using quantitative polymerase chain reaction.Results:A total of 127 compounds and 184 proteins were identified as potential active ingredients and putative liver cancer-related targets.Additionally,1,899 liver cancer targets,279 transcriptome targets,and 3 pathways(p53 signaling pathway,apoptosis and PI3K-Akt pathway)were collected.The FZHY-targets-liver cancer interaction network was constructed.IC50 of FZHY lyophilized powder solution to liver cancer was 5.13 mg/mL(IC50=5.13 mg/mL).FZHY treatment led to an increase in the ratio of cell apoptosis and induced mitochondrial membrane potential damage,resulting in an increase in the number of dead cells.The expression levels of CCNB1 and BIRC5 were induced with FZHY treatment,while the expression levels of AKR1C3 and IGF2 were reduced.Conclusion:FZHY promotes apoptosis of liver cancer cells
